News Releases

Penn researchers will present clinical trial results, new data on FLASH radiation therapy, updates on expanding global access to radiation therapy, and more at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting.

Adults with hemophilia B saw their number of bleeding episodes drop by an average of 71 percent after a single infusion of gene therapy, according to newly published clinical trial results that formed the basis of an FDA approval earlier this year.

Julia “Julie” Borrelli has been appointed chair of the Abramson Cancer Center Director's Leadership Council, succeeding Richard S. Schiffrin, Esq, who served as chair for five years. Borelli’s appointment becomes effective in November 2024.

Patients with a rare inherited disease affecting their sight experienced quick vision improvements that sustained for the full year-long study.

Taking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, according to a new study led by researchers from Penn.

A new tool for monitoring immune health patterns over time reveals how a pair of checkpoint inhibitor therapies works together to recruit new cancer-fighting T cells with every infusion.

The University of Pennsylvania and the Parker Institute for Cancer Immunotherapy have renewed their collaboration to advance cancer immunotherapy research at Penn Medicine’s Abramson Cancer Center.